Hanmi Pharm Co Ltd saw its shares decline 7.2% to close at ₩501,000 on Tuesday, trimming back gains from a sharp one-day advance in the session prior. The earlier surge - a nearly 30% jump in a single trading day - followed Hanmi's announcement of an exclusive global licensing agreement with Genentech, a subsidiary of Roche, for the experimental obesity candidate HM17321.
Under the terms disclosed, the agreement holds a total potential value of up to $2.3 billion, inclusive of development, regulatory, and commercial milestone payments. Genentech is to pay a $190 million non-refundable upfront fee as part of the deal. That upfront payment amounts to roughly 8% of the contract's total potential value. The licensing grant gives Genentech the worldwide rights to develop, manufacture, and commercialize HM17321 outside of South Korea.
Tuesday's decline was largely a correction after the prior session's outsized move. Market action fit a common pattern of post-catalyst profit-taking: the stock had already climbed about 62% over the three weeks before the Genentech announcement, leaving the share price extended relative to near-term support levels. Traders noted a wide intraday trading band on Tuesday, with prices ranging between ₩464,500 and ₩553,000, reflecting a tug-of-war between investors locking in recent gains and others still attracted to the strategic and commercial implications of the licensing agreement.
At the broader market level, the KOSPI posted a marginal rise on Tuesday following a day of sharp losses in the previous session.
Market context
The move highlights how a material corporate development - in this case a high-value licensing pact for an experimental drug candidate - can trigger rapid repositioning by market participants. A substantial non-refundable upfront payment and an agreement that confers broad development and commercialization rights are the explicit deal features cited by investors in assessing the announcement.
Trading dynamics
Price action on Tuesday emphasized both the immediate profit-taking response and continued interest in the long-term potential of the deal. The recorded intraday low and high show that while some sellers were quick to realize gains, there remained buying interest supporting the shares well above earlier support levels.
Investors and market watchers will likely continue to monitor Hanmi's share performance in the wake of the licensing announcement and any further detail the company or Genentech provides on development timelines and milestone triggers.